Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status

Lowe, Natalie; Bernstein, Jonathan M; Mais, Kathleen L; Garcez, Kate; Lee, Lip W; Sykes, Andrew J; Thomson, David J; Homer, Jarrod J; West, Catharine M L; Slevin, Nicholas J

doi:10.1007/s00432-017-2553-9

Cited by 5 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Platinum-based combination chemotherapy regimens have been widely used in clinical practice. In recent years, a number of clinical trials have confirmed that TPF regimen (docetaxel, cisplatin and 5-fluorouracil) may achieve a higher rate of remission without significantly increasing severe adverse reactions (2,(8)(9)(10). Currently, TPF regimen is becoming the first choice of ICT for locally advanced SCCHN.…”

Section: Discussionmentioning

confidence: 99%

Three therapeutic regimens based on induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: a single center experience

Jiang¹,

Guo²,

Wang³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

Background: This study aimed to compare three different therapeutic models based on regional control and the outcome of locally advanced squamous cell carcinoma of the head and neck (SCCHN) after induction chemotherapy (ICT). Methods: One hundred and twenty patients with locally advanced SCCHN were retrospectively reviewed and divided into three groups. Patients in Group A received induction chemotherapy + concurrent chemoradiotherapy (ICT + CCRT). Patients in Group B received induction chemotherapy + radical surgery + adjuvant radiotherapy with or without chemotherapy (ICT + Surgery + RT/CRT). Patients in Group C received induction chemotherapy + planned neck dissection + concurrent chemoradiotherapy (ICT + PND + CCRT). The clinicopathological characteristics, locoregional recurrence (LR), distant metastasis (DM), and overall survival (OS) were compared among them.Results: The median follow-up time was 20 months. In Group A, Group B and Group C, the 3-year OS was 69.7%, 72.9%, and 65.5% respectively. The LR rate was 35.1%, 26.2%, and 42.9%, respectively. The DM rate was 10.5%, 31.0%, and 9.5%, respectively. There were no significant differences in OS and LR among three groups. The DM in Group B was significantly higher than that in Group A (P<0.05), and was probably higher than that in Group C (P=0.06). Conclusions:Locally advanced SCCHN has a poor prognosis, and the first treatment is critical.Individualized therapeutic regimen based on the response of ICT could be an ideal solution. As cervical metastatic lymph nodes are less sensitive to ICT than primary tumors, PND before radiation therapy might improve the regional control and throat function preservation. A multidisciplinary team (MDT) collaboration is important throughout the treatment process.

show abstract

Section: Discussionmentioning

confidence: 99%

Three therapeutic regimens based on induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: a single center experience

Jiang¹,

Guo²,

Wang³

et al. 2020

Transl Cancer Res TCR

View full text Add to dashboard Cite

show abstract

“…Currently, a combination between platinum, taxanes, and fluorouracil (TPF) is considered to be the optimal treatment, with superior results in induction both compared to the platinum–fluorouracil regimen and compared to the platinum–taxane combination. Haddad et al mention the benefit of the TPF regime in survival and in the preservation of the organ, being recommended both for cases with a poor prognosis and for reducing the risk of distant metastases or loco-regional failure in operable cases or those with a good prognosis [ 26 , 27 , 28 ].…”

Section: The Multidisciplinary Approach In Locally Advanced Hnc: Chal...mentioning

confidence: 99%

Image Guided Radiotherapy (IGRT) and Delta (Δ) Radiomics—An Urgent Alliance for the Front Line of the War against Head and Neck Cancers

Mireștean

Iancu

2023

Diagnostics

View full text Add to dashboard Cite

The identification of a biomarker that is response predictive could offer a solution for the stratification of the treatment of head and neck cancers (HNC) in the context of high recurrence rates, especially those associated with loco-regional failure. Delta (Δ) radiomics, a concept based on the variation of parameters extracted from medical imaging using artificial intelligence (AI) algorithms, demonstrates its potential as a predictive biomarker of treatment response in HNC. The concept of image-guided radiotherapy (IGRT), including computer tomography simulation (CT) and position control imaging with cone-beam-computed tomography (CBCT), now offers new perspectives for radiomics applied in radiotherapy. The use of Δ features of texture, shape, and size, both from the primary tumor and from the tumor-involved lymph nodes, demonstrates the best predictive accuracy. If, in the case of treatment response, promising Δ radiomics results could be obtained, even after 24 h from the start of treatment, for radiation-induced xerostomia, the evaluation of Δ radiomics in the middle of treatment could be recommended. The fused models (clinical and Δ radiomics) seem to offer benefits, both in comparison to the clinical model and to the radiomic model. The selection of patients who benefit from induction chemotherapy is underestimated in Δ radiomic studies and may be an unexplored territory with major potential. The advantage offered by “in house” simulation CT and CBCT favors the rapid implementation of Δ radiomics studies in radiotherapy departments. Positron emission tomography (PET)-CT Δ radiomics could guide the new concepts of dose escalation on radio-resistant sub-volumes based on radiobiological criteria, but also guide the “next level” of HNC adaptive radiotherapy (ART).

show abstract

Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial

Keil

Hartl²,

Altorjai

et al. 2021

European Journal of Cancer

View full text Add to dashboard Cite

Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status

Cited by 5 publications

References 52 publications

Three therapeutic regimens based on induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: a single center experience

Three therapeutic regimens based on induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: a single center experience

Image Guided Radiotherapy (IGRT) and Delta (Δ) Radiomics—An Urgent Alliance for the Front Line of the War against Head and Neck Cancers

Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial

Contact Info

Product

Resources

About